NF1 and plexiform neurofibroma: Resistance to purinergic agonist is rescued in Nf1 mutant SCs by increasing levels of purinergic stimulation in vitro, and systemic administration of ATP reduced cell proliferation in mouse neurofibroma in vivo (Figs. 5, 6).